Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2008

View Archived Issues

Recent AstraZeneca patent imparts new HNE inhibitors

Regression of corneal neovascularization with novel antisense oligonucleotide GS-101

Vorinostat shows efficacy in glioblastoma multiforme

Intercell receives further payment as part of strategic alliance with Novartis

Ipsen starts E.U. filing process for Decapeptyl 6-month formulation

Ligand to acquire Pharmacopeia

Merck & Co. and Japan Tobacco enter licensing agreement for JTT-305 for osteoporosis

Novartis commences "squeeze out" procedure for remaining Speedel shares

Osiris completes enrollment of stem cell trial in COPD

Roche acquisition of Arius Research complete

Summit signs agreement with Orient Pharma to advance SMT-D-001 program

Takeda submits NDA to the FDA for alogliptin/Actos tablet for type 2 diabetes

Design, preclinical antiinflammatory activity of AN-2898 detailed

Recent results show biliverdin to ameliorate ischemic brain injury in rats

Savient provides business development update for pegloticase

CHMP recommends marketing authorization for Azarga in open-angle glaucoma

New antidepressant agents disclosed in recent patents

Synta reports new immunosuppressant agents in recent patent

CHMP recommends variations to marketing authorization of Cancidas

FDA grants approval to Alimta in first-line treatment of nonsquamous NSCLC

Synvista receives approval to commence phase II SYI-2074 trial in psoriasis

Takeda submits NDA for alogliptin in Japan

Takeda submits NDA in Japan for Actos orally disintegrating tablets

TransMolecular starts dosing in phase I/II radiolabeled TM-601 trial in glioma

VGX begins follow-on phase I study for antiinflammatory compound VGX-1027

Antisoma initiates phase II trial of AS-1402 in breast cancer

Arana Therapeutics files IND for lead antiinflammatory candidate ART-621

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...